Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24141268 | 1.00 | TDP1 (0.42) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23115361 | 0.99 | TDP1 (0.41) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23115369 | 0.98 | TDP1 (0.41) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23115411 | 0.96 | TDP1 (0.42) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23132235 | 0.96 | TDP1 (0.42) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23115345 | 0.95 | TDP1 (0.41) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL27410910 | 0.94 | ALDH1A1 (0.40) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL23115401 | 0.94 | ALDH1A1 (0.40) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL25204665 | 0.94 | CA12 (0.44) | TDP1DNM1DGKAMEN1GAA | |
| SCHEMBL25239638 | 0.94 | CA12 (0.44) | TDP1DNM1DGKAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240216288-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-04 | — | — | US | disclosed |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-06-27 | — | — | US | disclosed |
| EP-4031524-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| WO-2021262909-A2 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | MODERNATX, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262909-A2 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | MODERNATX, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-03-25 | — | — | US | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055833-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216288-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS AND USES THEREOF | PCCA, ACACA, PC | TDP1 3780/4885DNM1 1600/4885DGKA 346/4885 |
| US-20240207374-A1 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | G6PC1, GNPDA1, GPI | TDP1 976/4885DNM1 2511/4885DGKA 166/4885 |
| US-12312293-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | TDP1 3263/4885DNM1 1019/4885DGKA 1377/4885 |
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | MMAB, NSUN3, MSH6 | TDP1 341/4885DNM1 2519/4885DGKA 2514/4885 |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | TDP1 3263/4885DNM1 1019/4885DGKA 1377/4885 |
| US-11066355-B2 | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | PLTP, LNPK, PLIN3 | TDP1 3263/4885DNM1 1019/4885DGKA 1377/4885 |
| US-20210087135-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | TDP1 3263/4885DNM1 1019/4885DGKA 1377/4885 |
| US-20220106259-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | TDP1 3263/4885DNM1 1019/4885DGKA 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.